CORRESPONDENCE
Postmenopausal osteoporosis, breast cancer, and aromatase inhibitor
Osteoporose pós-menopausa, câncer de mama e o inibidor da aromatase
Somsri WiwanitkitI; Viroj WiwanitkitII
IWiwanitkit House, Bangkhae, Bangkok, Thailand
IIHainan Medical University, China, Faculty of Medicine, University of Nis, Serbia, Joseph Ayobabalola University, Nigeria
Corresponding author Corresponding author: Somsri Wiwanitkit Wiwanitkit House, Bangkhae Bangkok Thailand 10160 E-mail: somsriwiwan@hotmail.com
Dear Editor,
The recent article on bone mineral density in postmenopausal women with and without breast cancer was very interesting. Conde et al. concluded that The prevalence of abnormal bone mineral density (BMD) was higher in postmenopausal breast cancer survivors (BCS) than in postmenopausal women without breast cancer".1 Certainly, the concern regarding osteoporosis in the cancerous patient is very important. As Conde et al. mentioned, "special vigilance and the adoption of interventions should be instituted early to minimize bone loss". Indeed, cancer therapy should also be focused on monitoring osteoporosis among cancerous patients. The use of aromatase inhibitor as an adjuvant therapy in breast cancer is quite intriguing.2 It was recently reported that the use of aromatase inhibitor significantly increased osteoporosis, especially at femur region.2
Conflicts of interest
The authors declare no conflicts of interest.
- 1. Conde DM, Costa-Paiva L, Martinez EZ, Pinto-Neto AM. Bone mineral density in postmenopausal women with and without breast cancer. Rev Assoc Med Bras. 2012;58(6):673-8.
- 2. Mutlu H, Aslan T, Yılmaz GS, Erden A, Cihan YB, Akca Z, et al. Osteoporosis associated with aromatase inhibitors is different from post-menopausal osteoporosis. Adv Lab Med Int. 2013;3(1):1-5.
Corresponding author:
Publication Dates
-
Publication in this collection
05 July 2013 -
Date of issue
June 2013